Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

Beijing Airdoc (北京鹰瞳科技) Pre-IPO - New PHIP Updates

Beijing Airdoc (北京鹰瞳科技) IPO - Reasonable Valuation for a Small Niche

Beijing Airdoc (北京鹰瞳科技) IPO Trading - Poor Demand but Could Still Do Well

Beijing Airdoc (北京鹰瞳科技) Pre-IPO - A Niche Field with Merits but Can It Sell?

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Beijing Airdoc Technology / Equity Capital Markets

<div><p><a href="https://www.smartkarma.com/entities/beijing-airdoc-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33524:1" rel="noopener">Beijing Airdoc Technology (BAT HK)</a> is looking to raise about US$300m in its upcoming Hong Kong IPO.</p></div><div><p>BAT is an AI-based medical device company with a focus on AI-empowered retina-based early detection, diagnosis and health risk assessment solutions.</p></div><div>
<p>The company’s AI-based Software as a Medical Device (SaMD), Airdoc-AIFUNDUS (1.0), was approved for auxiliary diagnosis of diabetic retinopathy. It was the first of its kind to obtain the Class III medical device certificate from the NMPA, enabling it to be used in hospitals in China to assist physicians with medical diagnoses.</p>
<p>In this note, we will take a look at the company’s updated results from its PHIP filing and share our thoughts on valuation.</p>
</div>

Beijing Airdoc Technology (BAT HK) is looking to raise about US$300m in its upcoming Hong Kong IPO.BAT is an AI-based medical device company with a focus on AI-empowered retina-based early detection, diagnosis and health risk assessment solutions.
The company’s AI-based Software as a Medical Device (SaMD), Airdoc-AIFUNDUS (1.0), was approved for auxiliary diagnosis of diabetic retinopathy. It was the first of its kind to obtain the Class III medical device certificate from the NMPA, enabling it to be used in hospitals in China to assist physicians with medical diagnoses.
In this note, we will take a look at the company’s updated results from its PHIP filing and share our thoughts on valuation.


Beijing Airdoc (北京鹰瞳科技) Pre-IPO - Updates on 1Q21 Results and Competition